Abdominal adiposity and cardiometabolic risk: Do we have all the answers?
Abdominal adiposity and cardiometabolic risk: Do we have all the answers?
复制标题
DOI：
10.1016/j.amjmed.2007.06.006
复制
发表时间：
2007-09-01
影响因子：
5.9
通讯作者：
Haffner, Steven M.
中科院分区：
文献类型：
--
作者：
Haffner, Steven M.
超重和肥胖，特别是腹部肥胖，增加2型糖尿病和心血管疾病（CVD）的风险。代谢综合征是一系列危险因素，包括甘油三酯升高、高密度脂蛋白胆固醇低、血压升高、空腹血糖升高和腹部肥胖，可在更大程度上预测CVD和糖尿病的发展。过量的腹部脂肪组织与胰岛素抵抗有关，胰岛素抵抗是2型糖尿病的前兆，并产生致动脉粥样硬化的炎症环境，其特征是高水平的C反应蛋白和其他炎症标志物（例如，例如，在一个实施例中，纤维蛋白原、纤溶酶原激活物抑制剂-1、细胞因子和粘附分子）。高水平的这些生物标志物与糖尿病和CVD的发病率增加相关。最近的证据表明，非酒精性脂肪肝患者肥胖、代谢综合征、胰岛素抵抗和/或2型糖尿病的发病率增加。相对较小的体重减轻可显著减少腹部脂肪组织，降低胰岛素抵抗，降低甘油三酯和低密度脂蛋白胆固醇，减少炎症，并降低总体心脏代谢风险。(C)2007爱思唯尔公司All rights reserved.
Overweight and obesity, particularly abdominal adiposity, increase the risk for type 2 diabetes mellitus and cardiovascular disease (CVD). Metabolic syndrome, a constellation of risk factors that includes elevated triglycerides, low high-density lipoprotein cholesterol, elevated blood pressure, elevated fasting glucose, and abdominal obesity, predicts the development of CVD and diabetes to an even greater degree. Excess abdominal adipose tissue is associated with insulin resistance, the precursor to type 2 diabetes, and creates an atherogenic inflammatory milieu, characterized by high levels of C-reactive protein and other inflammatory markers (e. g., fibrinogen, plasminogen activator inhibitor-1, cytokines, and adhesion molecules). High levels of these biomarkers correlate with an increased incidence of diabetes and CVD. Recent evidence suggests that patients with nonalcoholic fatty liver disease have an increased incidence of obesity, metabolic syndrome, and insulin resistance and/or type 2 diabetes. Relatively small reductions in body weight may significantly reduce abdominal adipose tissue, reduce insulin resistance, lower triglycerides and low-density lipoprotein cholesterol, reduce inflammation, and decrease overall cardiometabolic risk. (C) 2007 Elsevier Inc. All rights reserved.